These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 25913291

  • 1. ARID1A expression in ovarian clear cell carcinoma with an adenofibromatous component.
    Nishikimi K, Kiyokawa T, Tate S, Iwamoto M, Shozu M.
    Histopathology; 2015 Dec; 67(6):866-71. PubMed ID: 25913291
    [Abstract] [Full Text] [Related]

  • 2. Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma.
    Xiao W, Awadallah A, Xin W.
    Int J Clin Exp Pathol; 2012 Dec; 5(7):642-50. PubMed ID: 22977660
    [Abstract] [Full Text] [Related]

  • 3. Ovarian Clear Cell Carcinoma Sub-Typing by ARID1A Expression.
    Choi JY, Han HH, Kim YT, Lee JH, Kim BG, Kang S, Cho NH.
    Yonsei Med J; 2017 Jan; 58(1):59-66. PubMed ID: 27873496
    [Abstract] [Full Text] [Related]

  • 4. Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases.
    Veras E, Mao TL, Ayhan A, Ueda S, Lai H, Hayran M, Shih IeM, Kurman RJ.
    Am J Surg Pathol; 2009 Jun; 33(6):844-53. PubMed ID: 19342944
    [Abstract] [Full Text] [Related]

  • 5. ARID1A mutations in endometriosis-associated ovarian carcinomas.
    Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih IeM, Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG.
    N Engl J Med; 2010 Oct 14; 363(16):1532-43. PubMed ID: 20942669
    [Abstract] [Full Text] [Related]

  • 6. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
    Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio MS, Gilks B, Mills GB, Huntsman DG, Carey MS.
    BMC Cancer; 2014 Feb 22; 14():120. PubMed ID: 24559118
    [Abstract] [Full Text] [Related]

  • 7. Expression and significance of ARID1A mRNA in endometriosis- associated ovarian cancer.
    Wang Q, Wang L, L Y, Ding X, Liu A.
    J BUON; 2017 Feb 22; 22(5):1314-1321. PubMed ID: 29135119
    [Abstract] [Full Text] [Related]

  • 8. Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis.
    Barreta A, Sarian LO, Ferracini AC, Costa LBE, Mazzola PG, de Angelo Andrade L, Derchain S.
    Hum Pathol; 2019 Mar 22; 85():72-81. PubMed ID: 30447298
    [Abstract] [Full Text] [Related]

  • 9. The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis.
    Chene G, Ouellet V, Rahimi K, Barres V, Provencher D, Mes-Masson AM.
    Int J Gynaecol Obstet; 2015 Jul 22; 130(1):27-30. PubMed ID: 25912412
    [Abstract] [Full Text] [Related]

  • 10. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma.
    Ayhan A, Mao TL, Seckin T, Wu CH, Guan B, Ogawa H, Futagami M, Mizukami H, Yokoyama Y, Kurman RJ, Shih IeM.
    Int J Gynecol Cancer; 2012 Oct 22; 22(8):1310-5. PubMed ID: 22976498
    [Abstract] [Full Text] [Related]

  • 11. BAF250a Expression in Atypical Endometriosis and Endometriosis-Associated Ovarian Cancer.
    Stamp JP, Gilks CB, Wesseling M, Eshragh S, Ceballos K, Anglesio MS, Kwon JS, Tone A, Huntsman DG, Carey MS.
    Int J Gynecol Cancer; 2016 Jun 22; 26(5):825-32. PubMed ID: 27051059
    [Abstract] [Full Text] [Related]

  • 12. Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers.
    Lowery WJ, Schildkraut JM, Akushevich L, Bentley R, Marks JR, Huntsman D, Berchuck A.
    Int J Gynecol Cancer; 2012 Jan 22; 22(1):9-14. PubMed ID: 22193641
    [Abstract] [Full Text] [Related]

  • 13. (Partial) Loss of BAF250a (ARID1A) in rectovaginal deep-infiltrating endometriosis, endometriomas and involved pelvic sentinel lymph nodes.
    Borrelli GM, Abrão MS, Taube ET, Darb-Esfahani S, Köhler C, Chiantera V, Mechsner S.
    Mol Hum Reprod; 2016 May 22; 22(5):329-37. PubMed ID: 26832958
    [Abstract] [Full Text] [Related]

  • 14. Clinicopathologic Significance of HNF-1β, AIRD1A, and PIK3CA Expression in Ovarian Clear Cell Carcinoma: A Tissue Microarray Study of 130 Cases.
    Ye S, Yang J, You Y, Cao D, Huang H, Wu M, Chen J, Lang J, Shen K.
    Medicine (Baltimore); 2016 Mar 22; 95(9):e3003. PubMed ID: 26945423
    [Abstract] [Full Text] [Related]

  • 15. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.
    Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O.
    Mod Pathol; 2012 Apr 22; 25(4):615-24. PubMed ID: 22157930
    [Abstract] [Full Text] [Related]

  • 16. Expression of platelet-derived growth factors and their receptors in ovarian clear-cell carcinoma and its putative precursors.
    Yamamoto S, Tsuda H, Takano M, Kita T, Kudoh K, Furuya K, Tamai S, Matsubara O.
    Mod Pathol; 2008 Feb 22; 21(2):115-24. PubMed ID: 18084257
    [Abstract] [Full Text] [Related]

  • 17. Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation?
    Samartzis EP, Samartzis N, Noske A, Fedier A, Caduff R, Dedes KJ, Fink D, Imesch P.
    Mod Pathol; 2012 Jun 22; 25(6):885-92. PubMed ID: 22301703
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas.
    Wiegand KC, Lee AF, Al-Agha OM, Chow C, Kalloger SE, Scott DW, Steidl C, Wiseman SM, Gascoyne RD, Gilks B, Huntsman DG.
    J Pathol; 2011 Jul 22; 224(3):328-33. PubMed ID: 21590771
    [Abstract] [Full Text] [Related]

  • 20. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
    Heckl M, Schmoeckel E, Hertlein L, Rottmann M, Jeschke U, Mayr D.
    PLoS One; 2018 Jul 22; 13(2):e0192881. PubMed ID: 29451900
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.